User:Mr. Ibrahem/Mepolizumab

Mepolizumab, sold under the brand name Nucala, is medication used to treat eosinophilic asthma, eosinophilic granulomatosis with polyangiitis, and hypereosinophilic syndrome. It is given by injection under the skin. Effects begin in about three days and can last up to 6 months.

Common side effects include headache, injection site reactions, and back pain. Other side effects may include anaphylaxis, shingles, and urinary tract infection. It should not be given to people with helminth infections. It is a monoclonal antibody which binds to and blocks interleukin-5 (IL-5) which decreases eosinophils.

Mepolizumab was approved for medical use in the United States and Europe in 2015. In the United Kingdom it costs about the NHS about £840 per dose. In the United States this amount costs about 3,300 USD.